High-dose chemotherapy with autologous stem cell support in patients with breast cancer (Q44526837)

3 December 2017

1 reference

title

High-dose chemotherapy with autologous stem cell support in patients with breast cancer (English)

1 reference

3 December 2017

1 reference

4

Champlin R

1 reference

3 December 2017

3

Buzdar AU

1 reference

3 December 2017

Rahman ZU

1

1 reference

3 December 2017

Hortobagyi GN

series ordinal

2

1 reference

3 December 2017

publication date

1 August 1998

1 reference

3 December 2017

published in

Cancer Treatment Reviews

1 reference

3 December 2017

volume

24

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

249-263

1 reference

The importance of dose intensity in chemotherapy of metastatic breast cancer

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Purging: the separation of normal from malignant cells for autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Peripheral blood stem cell harvesting and CD34-positive cell selection.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

The immunological treatment of human marrow in vitro in transplantation biology.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Multivariate analysis of prognostic factors in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Complete Remissions in Metastatic Breast Cancer Treated with Combination Drug Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990060-3

7 January 2021

10.1016/S0305-7372(98)90060-3

Identifiers

DOI

1 reference

3 December 2017

1 reference